| |
|
|
|
|
|
The COBAS® AmpliPrep/COBAS® TaqMan® HBV Test is a fully automated in vitro nucleic acid amplification test for the quantitation of Hepatitis B virus (HBV) in human plasma, using the COBAS® AmpliPrep Instrument for automated sample processing and the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer for automated amplification and detection.
Highly Sensitive & Accurate
The COBAS® AmpliPrep/COBAS® TaqMan® HBV Test offers:
A fully automated, docked platform that combines the COBAS® AmpliPrep Instrument for automated sample preparation and the COBAS® TaqMan® 96 Analyzer for automated real
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
The COBAS® AmpliPrep/COBAS® TaqMan® HCV Test is a fully automated in vitro nucleic acid amplification test for the quantitation of Hepatitis C virus (HCV) in human plasma and serum, using the COBAS® AmpliPrep Instrument for automated sample processing and the COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer for automated amplification and detection.
Highly Sensitive & Accurate
The COBAS® AmpliPrep/COBAS® TaqMan® HCV Test offers:
A fully automated, docked platform that combines the COBAS® AmpliPrep Instrument for automated sample preparation and the COBAS® TaqMan® 96 Analyzer for auto
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is a fully automated sample preparation, amplification and detection test that utilizes real-time PCR and fluorescence resonance energy transfer (FRET) to detect and quantify Human Immunodeficiency Virus Type 1 (HIV-1) RNA. This test aids physicians in patient prognosis and viral load monitoring.
Highly Sensitive & Accurate
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test offers:
A fully automated, docked platform that combines the COBAS® AmpliPrep Instrument for automated sample preparation and the COBAS® TaqMan® 96 Analyzer for automated real
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
West Nile virus (WNV) is a mosquito-borne virus that can cause mild, flu-like symptoms as well as severe neurological disease. The first confirmed U.S. death resulting from WNV transmission through donated blood was reported in 2002. In the fall of that year, the FDA challenged industry to develop a test for the direct detection of WNV in donated blood. Gen-Probe met this challenge in June of 2003, and since then U.S. blood centers have used the PROCLEIX WNV assay to screen tens of millions of units of donated blood, intercepting more than 1,500 infected donations. The PROCLEIX WNV Assay was
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
In six short years, the West Nile virus has established itself as a fact of life in North America. The West Nile virus is a mosquito borne virus that finds its way to humans through mosquito bites. The vast majority of infected people don’t even feel sick but people older than 50 years with chronic medical conditions and those receiving immunosuppression are at higher risk of severe disease, which may include meningoencephalitis and death.
As each new season approaches, scientists attempt to predict how bad the season will be, but history shows that the West Nile virus defies prognostication
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
West Nile virus (WNV) causes severe neurological disease and fatalities in both human and animal hosts. There is currently no effective vaccine or antiviral drug to protect against WNV infection. The West Nile virus NS3 protease, essential for the proteolytic processing of the viral polyprotein precursor, is a promising target for the development of anti-WNV drugs. The SensoLyte™ 440 West Nile Virus Protease Assay Kit provides a convenient homogenous assay for high throughput screening of WNV protease inhibitors and for continuous assay of NS3 protease activity using a fluorogenic Pyr-RTKR-AMC
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
West Nile virus (WNV) causes severe neurological disease and fatalities in both human and animal hosts. There is currently no effective vaccine or antiviral drug to protect against WNV infection. West Nile virus NS3 protease, essential for the proteolytic processing of the viral polyprotein precursor, is a promising target for the development of anti-WNV drugs. The SensoLyte™ 570 West Nile Virus Protease Assay Kit provides a convenient homogeneous assay for high throughput screening of WNV protease inhibitors and for continuous assay of NS3 protease activity using QXLTM570/5-TAMRA FRET substra
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
A simple rapid screening test for the detection of West Nile Virus and/or St. Louis Encephalitis Virus in mosquitoes.
Results in 15 minutes
Easy to interpret
Stable at room temperature
Very specific-no false positives
Recognized by the Center for Disease Control (CDC) as an effective rapid screening test
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
The West Nile Virus (WNV) NS3 protease is absolutely essential (along with viral-encoded cofactor NS2B) for post-translational processing of a viral polypeptide precursor in infected host cells. This polypeptide provides the structural and functional viral proteins, and inhibition of its processing could represent a potential treatment for viral infections. Thus, this protease has become one of the key targets for developing anti-WNV drugs. Recombinant WNV NS3 protease can be used in enzyme assay with SensoLyte™ 440, or 570 WNV protease Assay Kits (Cat#72079, 72080) for screening of WNV NS3 in
|
Company:
Date:
November 18, 2008
|
|
|
|
|
|
|
|
|
|
Spectral’s RapidWN™ West Nile Virus IgM Test is the first immunochromatographic test for West Nile virus IgM which can be used by public health laboratories, clinical diagnostic laboratories, research institutes and universities.
The test is a quick and sensitive pre-screening test used for detecting West Nile virus specific IgM in patients’ serum and plasma.
|
Company:
Date:
March 03, 2009
|
|
|
|
|
|